Mark Ballantyne


I love the challenges of working with technology and life sciences companies as they evolve from startups to public companies.

Mark Ballantyne focuses his practice on representing IPO ready and publicly traded life sciences and technology companies, as well as underwriters.

Download full bio 


  • BigCommerce Holdings – $345 Million Convertible Senior Notes Offering 

  • Legend Biotech - $487 Million IPO 

  • LogicBio Therapeutics – $80.5 Million IPO 

  • Verrica Pharmaceuticals – $86 Million IPO 

  • Translate Bio – $122 Million IPO 

  • View all


  • University of Richmond School of Law
    JD, magna cum laude, Order of the Coif, McNeill Law Society, 2012

  • Wake Forest University
    BA, 2008

Admissions & Credentials


Rankings & Accolades

    Best Lawyers: Ones to Watch - Securities/Capital Markets Law and Venture Capital Law (2021)